PER OLOF WALLSTRÖM LEAVES KARO BIO

PER OLOF WALLSTRÖM LEAVES KARO BIO

STOCKHOLM, February 16, 2010. Karo Bio AB (publ) (Reuters: KARO.ST) today
announced that Per Olof Wallström, President and CEO of Karo Bio AB for the past
five years, has decided to resign to pursue other opportunities.  He intends to
stay with the company until his successor has been appointed.  

"P.O. has been a dedicated and effective leader of our company", said Dr. Leon
Rosenberg, Chair of Karo Bio's Board of Directors.  "He has moved two projects
into early and mid-stage clinical development, recruited key people to his
senior management team, and completed successfully three fund-raising campaigns.
 The Board wishes him all success in his future activities."  A search for
Wallström's successor has been initiated.



For more information please contact:
Leon Rosenberg, Chairman of the Board
Tel: +46 70 218 9334

Birgit Stattin Norinder, Board member
Tel: +46 70 662 6180



About Karo Bio
Karo Bio is a drug discovery and development company specializing in
endocrinology and targeting nuclear receptors as target proteins for the
development of novel pharmaceuticals. The company has a project portfolio with
innovative molecules that primarily target dyslipidemia, CNS-disorders,
inflammation, and women's health. In these areas, there are significant market
opportunities and a clear need for pharmaceuticals with new mechanisms of
action. Karo Bio develops compounds aimed at treating broad patient populations
up to clinical proof of concept before out-licensing. In therapeutic niche
areas, Karo Bio has the capacity to bring selected compounds into late stage
clinical development and, potentially, to the market. In addition to the
proprietary projects, Karo Bio has three strategic collaborations with
international pharmaceutical companies for development of innovative therapies
for the treatment of common diseases. Karo Bio is listed on NASDAQ OMX Stockholm
since 1998 (Reuters: KARO.ST).


This press release is also available online at: www.karobio.com and
www.newsroom.cision.com